GlaxosmithKline gets $300m to 23andme · Articles · Global Corporate Venturing
Venture Houston 2018
Skip Content

26 July 2018

GlaxosmithKline gets $300m to 23andme

The genetic data services provider raised the cash from GSK as part of a collaboration deal, taking its total funding past $790m.

Author: Robert Lavine, News Editor

Pharmaceutical firm GlaxoSmithKline (GSK) has invested $300m in US-based DNA services provider 23andme as part of a four-year collaboration agreed by the companies yesterday.